English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Review question / Objective: What are the evidence on safety and efficacy of pharmacological treatments used in MIS-C management? Condition being studied: Multisystem Inflammatory Syndrome in Children (MIS-C) - In early 2020, rare cases associated with SARS-CoV-2 were reported in children known as Multisystem Inflammatory Syndrome in Children (MIS-C) by the Centers for Disease Control and Prevention. This condition which is also known as Paediatric Inflammatory Multisystem Syndrome (PIMS) was initially presented as Kawasaki disease as it has similar symptoms. However, MIS-C was then defined as a new disease because of several differences in features. This emergence addresses the need for safe and efficient treatment approaches.

Safety And Efficacy of Pharmacological Approaches Available for Multisystem Inflammatory Syndrome in Children (Mis-C): A Systematic Review